Brandy D. Gunsolus, DCLS, MLS(ASCP)CM, describes the manifestation of systemic mastocytosis in individuals based on skin tone and gender. Dr Gunsolus also provides insights for helping to ensure that patients receive an accurate diagnosis.
John M. Fahrenholz, MD, Vanderbilt University Medical Center, Nashville, Tennessee, discusses questions about nonadvanced systemic mastocytosis submitted by participants. Topics include triggers for mast cell activation, management strategies…
Systemic mastocytosis, a rare blood disorder, affects the entire body. There are many challenges associated with living with this systemic mastocytosis that are centered around reducing the frequency…
Avapritinib, branded as Ayvakit, became the first FDA-approved treatment for indolent systemic mastocytosis (ISM) in 2023, marking a major advancement for patients. ISM, driven by the KIT D816V…
Distinguishing indolent from advanced systemic mastocytosis is notoriously complex, even for seasoned clinicians. To simplify diagnosis, researchers developed a mathematical model using basic lab values, achieving 93% predictive…
